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OBJECTIVES The aim of this study was to test the hypothesis that the angiotensin II type 1 receptor blocker
(ARB) candesartan can reduce the risk of stroke in elderly patients with isolated systolic
hypertension (ISH).
BACKGROUND Isolated systolic hypertension is the predominant form of hypertension in the elderly, and
stroke is the most common cardiovascular (CV) complication.
METHODS In the Study on Cognition and Prognosis in the Elderly (SCOPE), 4,964 patients age 70 to
89 years were randomly assigned to double-blind candesartan or placebo with open-label
antihypertensive therapy (mostly thiazide diuretics) added as needed to control blood
pressure. Of the 4,964 patients, 1,518 had ISH (systolic blood pressure 160 mm Hg and
diastolic blood pressure 90 mm Hg). The present study is a predefined subgroup analysis
of outcome results in the ISH patients.
RESULTS Of the ISH patients, 754 were randomized to the candesartan group and 764 to the control
group. Over the study period, blood pressure was reduced by 22/6 mm Hg in the candesartan
group and by 20/5 mm Hg in the control group (difference between treatments 2/1 mm Hg;
p  0.101 and 0.064). A total of 20 fatal/non-fatal strokes occurred in the candesartan group
(7.2/1,000 patient-years) and 35 in the control group (12.5/1,000 patient-years); relative risk
(RR) was 0.58 (95% confidence interval 0.33 to 1.00), that is, a RR reduction of 42% (p 
0.050 unadjusted, p  0.049 adjusted for baseline risk). There were no marked or statistically
significant differences between the treatment groups in other CV end points or all-cause
mortality.
CONCLUSIONS In elderly patients with ISH, antihypertensive treatment based on the ARB candesartan
resulted in a significant 42% RR reduction in stroke in comparison with other antihyperten-
sive treatment, despite little difference in blood pressure reduction. (J Am Coll Cardiol
2004;44:1175–80) © 2004 by the American College of Cardiology Foundationh
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dsolated systolic hypertension (ISH) is the most common
orm of hypertension in the elderly and a major risk
actor for cardiovascular (CV) disease (1,2). Large-scale,
lacebo-controlled clinical trials have demonstrated the
alue of treating older patients with ISH. In the Systolic
ypertension in the Elderly Program (SHEP), anti-
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3), and in the Systolic Hypertension in Europe (Syst-Eur)
tudy, active treatment decreased the occurrence of stroke
y 42% (4). Stroke prevention is exceedingly important
ecause it is now the primary hypertensive complication of
ntreated hypertension in the elderly. A recent meta-
nalysis suggested that in studies carried out since the early
990s, the incidence of stroke exceeds that of myocardial
nfarction (5).
Although the benefit of treating ISH in older hyperten-
ive populations has been clearly established (3,4), it is not
lear whether specific drug therapies confer additional
enefit beyond blood pressure control. The only publication,
o far, is based on an analysis of patients with ISH and
lectrocardiographic evidence of left ventricular hypertro-
hy, participating in the Losartan Intervention For End-
oint reduction (LIFE) study (6). This LIFE substudy
emonstrated substantial reduction in CV mortality, stroke,
nd new-onset diabetes mellitus with the angiotensin II
t
m
b
p
(
t
o
t
c
m
t
r
p
m
e
h
o
t
c
T
(
b
c
t
l
t
r
s
o
a
b
P
D
(
y
m
M
o
t
e
1
t
t
o
c
c
o
t
m
d
r
w
r
a
t
m
a
e
t
C
n
a
m
m
r
c
t
r
p
a
t
b
p
c
S
t
p
“
C
t
a
a
O
l
p
p
c
b
m
1176 Papademetriou et al. JACC Vol. 44, No. 6, 2004
Stroke Prevention in ISH September 15, 2004:1175–80ype 1 (AT1) receptor blocker (ARB) losartan-based treat-
ent as compared with the beta receptor blocker atenolol-
ased treatment in patients with ISH, despite similar blood
ressure reduction.
The Study on Cognition and Prognosis in the Elderly
SCOPE) was designed as the first large-scale clinical trial
o determine the effects of an ARB on CV and cognitive
utcomes in elderly patients with mild to moderate hyper-
ension (7). The SCOPE was initially conceived as a
omparison of candesartan with placebo. However, treat-
ent guidelines changed during the recruitment phase of
he study, and the protocol was amended, for ethical
easons, to recommend the addition of open-label antihy-
ertensive therapy in patients whose blood pressure re-
ained too high. As a result, a large proportion of patients,
specially in the “placebo” group, received additional anti-
ypertensive medication, and the trial became a comparison
f a candesartan-based regimen with a regimen not con-
aining candesartan. Indeed, 84% of the patients in the
ontrol group received active antihypertensive medication.
he primary results from the SCOPE have been published
8). The mean blood pressure reduction was pronounced in
oth the candesartan group (21.7/10.8 mm Hg) and the
ontrol group (18.5/9.2 mm Hg, mean difference between
reatments: 3.2/1.6 mm Hg). Non-fatal stroke was 27.8%
ower in patients treated with candesartan compared with
hose in the control group (p  0.04), and all stroke was
educed by 23.6% (p  0.06). Other CV events were not
ignificantly different between groups.
The present study is a predefined subgroup analysis of
utcome results in the SCOPE patients with ISH, defined
s systolic blood pressure (SBP)160 mm Hg and diastolic
lood pressure (DBP) 90 mm Hg.
ATIENTS AND METHODS
etails on study methods have been previously published
7,8). In brief, hypertensive patients between 70 and 89
ears of age, with treated or untreated SBP of 160 to 179
m Hg, or DBP of 90 to 99 mm Hg, or both, and a Mini
Abbreviations and Acronyms
ARB  angiotensin II type 1 receptor blocker
AT1  angiotensin II type 1
CI  confidence interval
CV  cardiovascular
DBP  diastolic blood pressure
HCTZ  hydrochlorothiazide
ISH  isolated systolic hypertension
LIFE  Losartan Intervention For Endpoint
reduction study
MMSE  Mini Mental State Examination
RR  relative risk
SBP  systolic blood pressure
SCOPE  Study on Cognition and Prognosis in the
Elderlyental State Examination (MMSE) score of 24 or higher mn two consecutive occasions, were eligible for enrollment in
he SCOPE study. Antihypertensive medications at study
ntry were standardized to hydrochlorothiazide (HCTZ)
2.5 mg daily at study enrollment and were continued
hroughout the study.
The study consisted of an open run-in period (one to
hree months) followed by a double-blind treatment period
f three to five years. Patients were randomized (1:1) by a
entral, computer-generated randomization schedule to re-
eive either candesartan 8 mg or a matching placebo tablet
nce daily in the morning. Study medication was doubled to
wo tablets once daily if, at any consecutive visits, the patient
et any of the following criteria: SBP 160 mm Hg,
ecrease in SBP of 10 mm Hg compared with the
andomization visit, or DBP above 85 mm Hg. Patients
ith SBP 160 mm Hg or DBP 90 mm Hg after
eceiving two tablets of study medication could receive
dditional antihypertensive medication. In accordance with
he protocol, HCTZ 12.5 mg daily was the preferred
edication to be added to study treatment. Subsequently,
ny other antihypertensive medication could be added,
xcluding ARBs or angiotensin-converting enzyme inhibi-
ors.
The primary end point of the SCOPE was a first major
V event (CV death, non-fatal myocardial infarction, or
on-fatal stroke). A number of secondary end points were
lso prespecified. These included cognitive function as
easured by the MMSE, dementia, total mortality, CV
ortality, fatal and non-fatal myocardial infarction (sepa-
ate and combined), fatal and non-fatal stroke (separate and
ombined), new-onset diabetes mellitus, and discontinua-
ion of study drug as a result of adverse events.
The study was conducted in accordance with the Decla-
ation of Helsinki and Good Clinical Practice. The study
rotocol and patient consent forms were approved by the
ppropriate ethics committee at each institution that par-
icipated in the study. Patients were recruited into the study
etween March 1997 and January 1999, and the follow-up
hase ended in March 2002. A total of 527 centers in 15
ountries, mainly in Europe, participated in the study.
tatistical methods. The analysis was conducted according
o the intention to treat and last value carried forward
rinciples. Differences between the treatment groups in
time to event” were analyzed with a log-rank test and in a
ox regression model. The p values for the interaction
reatment by subgroups (ISH/non-ISH) were calculated in
Cox regression analysis. Adjustment for baseline CV risk
ccording to the criteria given in the 1999 World Health
rganization-International Society of Hypertension guide-
ines (9) was done in a Cox regression model to account for
ossible differences in risk at baseline. Differences in pro-
ortions of patients with an event were analyzed using the
hi-square test. The continuous variables, such as change in
lood pressure or MMSE score from baseline, were sym-
etrically distributed and tested in an analysis of covariance
odel, with prespecified factors adjusting for country and
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September 15, 2004:1175–80 Stroke Prevention in ISHaseline value. Two-sided p values and 95% confidence
ntervals (CI) are used in this report. Data are shown as
ean values with standard deviation where appropriate.
ESULTS
f the 4,964 randomized patients, 1,518 met the criteria for
SH. The average duration of follow-up in ISH patients was
.6 years corresponding to 5,506 patient-years. Of the ISH
atients, 754 were randomized to the candesartan arm and
64 were randomized to the control arm. One patient only
in the candesartan arm) was lost to follow-up, that is, no
ata were available after randomization. The baseline char-
cteristics were generally similar in the two treatment
roups (Table 1). However, the distribution of CV risk
ndicated a slightly higher risk in the candesartan group
han in the control group. Compared with non-ISH pa-
ients, patients with ISH were older, had lower DBP, and
ere less likely to have received previous antihypertensive
edication (data not shown). The average age for all ISH
atients was 77.1 years, and more than 26% of them were
ver the age of 80 years. Approximately 64% of them were
omen, and about 46% of all patients were previously
reated for hypertension. A small percentage of patients
able 1. Baseline Characteristics of Patients With ISH*
Characteristics
Candesartan
(n  754)
Control
(n  764)
ge (yrs, mean) 77.3 76.9
ge 80 yrs (%) 28.2 25.1
omen (%) 63.3 65.3
MSE (score, mean) 28.6 28.6
lood pressure (mm Hg, mean) 168.7/82.3 169.3/82.5
reviously treated hypertension (%) 47.7 45.2
revious MI (%) 4.2 4.5
revious stroke (%) 4.4 3.9
trial fibrillation (%) 2.4 2.9
bnormal ECG (%) 27.6 28.8
iabetes (%) 13.5 11.0
mokers (%) 10.1 8.9
eart rate (beats/min, mean) 74.2 73.7
MI (kg/m2, mean) 26.7 26.3
erum cholesterol (mmol/l, mean) 6.2 6.2
erum creatinine (mol/l, mean) 91.3 90.9
reated with
Lipid-lowering drug (%) 10.3 9.4
ASA/NSAID (%) 28.5 24.9
Psychopharmacologic drug (%) 11.3 10.3
ducation
Less than primary school (%) 7.0 7.7
Primary school (%) 39.7 39.5
More than primary school (%) 48.3 48.2
University (%) 5.0 4.6
ardiovascular risk
High or very high (%) 38.9 32.5
Medium (%) 61.1 67.5
ISH  SBP 160 mm Hg and DBP 90 mm Hg.
ASA  aspirin; BMI  body mass index; DBP  diastolic blood pressure; ECG
electrocardiogram; ISH  isolated systolic hypertension; MI  myocardial
nfarction; MMSE  Mini Mental State Examination; NSAID  nonsteroidal
nti-inflammatory drug; SBP  systolic blood pressure.qually distributed among the two groups had a history of crevious myocardial infarction, stroke, or diabetes, and
pproximately 10% of them were current smokers. About
.7% of the patients had a history of atrial fibrillation, and
pproximately 28% had abnormal electrocardiograms ac-
ording to the investigator. Mean baseline blood pressure
as similar in the two groups.
As a consequence of the treatment schedule specified in
he study protocol, only 18% of the patients in the control
roup received placebo alone, and the vast majority (82%)
eceived active antihypertensive medication (Table 2). Fif-
een percent remained on the low-dose HCTZ (12.5 mg)
lready given at baseline, and 67% received open-label
dd-on therapy. In the candesartan group 26% of the
atients received candesartan alone, 21% remained on the
ow-dose HCTZ given at baseline, and 53% received
pen-label add-on therapy.
lood pressure response. During the follow-up period,
lood pressure was reduced significantly in both the cande-
artan and the control groups (Fig. 1). At the end of the
tudy, the average decline in blood pressure compared with
aseline was 22.2/6.0 mm Hg in the candesartan group and
0.2/4.8 mm Hg in the control group. In both groups, the
BP and DBP reductions were significant (p  0.001). The
able 2. Use of Different Antihypertensive Medication During
he Study (% Patients)
Antihypertensive Treatment
Candesartan
(n  754)
Control
(n  764)
tudy drug only 26 18
tudy drug  HCTZ 12.5 mg
from baseline
21 15
dd-on treatment 53 68
Diuretic* 36 46
Beta-blocker 19 27
Calcium channel blocker 21 30
ACE inhibitor 8 12
ARB 3 3
A dose increase from HCTZ 12.5 mg baseline treatment or HCTZ started after
andomization.
ACE  angiotensin-converting enzyme; ARB  angiotensin II type 1 receptor
locker; HCTZ  hydrochlorothiazide; ISH  isolated systolic hypertension.
igure 1. Systolic and diastolic blood pressure during the study. Solid lines
control group; dashed lines  candesartan group. LVCF  last valuearried forward.
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Stroke Prevention in ISH September 15, 2004:1175–80verage difference in blood pressure decline between the two
roups was 2.0 mm Hg (95% CI0.4 to 4.4, p 0.064) for
BP and 1.2 mm Hg (95% CI 0.1 to 2.4, p  0.064) for
BP in favor of the candesartan group.
V events and other end points. In patients with ISH, a
rst major CV event (CV death, non-fatal myocardial
nfarction, or non-fatal stroke) occurred in 75 patients in the
andesartan group (27.3 events/1,000 patient-years) and in
5 patients in the control group (30.8 events/1,000 patient-
ears), corresponding to a relative risk (RR) of 0.89 (95% CI
.65 to 1.21, p  0.20) (Table 3). A first stroke, fatal or
on-fatal, occurred in 20 of the patients receiving
andesartan-based therapy (7.2 events/1,000 patient-years)
nd in 35 of the patients in the control group (12.5
vents/1,000 patient-years), giving a RR of 0.58 (95% CI
.33 to 1.00, p 0.05) (Table 3 and Fig. 2). When adjusted
or the slightly higher CV risk at baseline in the candesartan
roup, the RR and its 95% CI changed marginally toward
ower values and the advantage of candesartan-based ther-
py was statistically significant (p  0.049). In the cande-
artan group, 2.7% of the patients suffered a stroke com-
ared with 4.6% in the control group. Thus, the absolute
isk reduction was 1.9 per 100 patients treated, that is, 53
atients needed to be treated with candesartan-based ther-
able 3. Clinical Outcomes in Patients with ISH
Rate, n (%)
Candesartan
(n  751–754)
Control
(n  761–764)
ajor CV event 75 (9.9) 85 (11.0)
V death 47 (6.2) 48 (6.3)
atal/non-fatal MI 23 (3.1) 25 (3.3)
atal/non-fatal stroke 20 (2.7) 35 (4.6)
atal MI 6 (0.8) 7 (0.9)
on-fatal MI 18 (2.4) 20 (2.6)
atal stroke 3 (0.4) 7 (0.9)
on-fatal stroke 17 (2.3) 28 (3.7)
otal mortality 82 (10.9) 90 (11.0)
RR and p values correspond to events/1,000 follow-up years, calculated from a Cox
CV  cardiovascular; ISH  isolated systolic hypertension; MI  myocardial inbFigure 2. Kaplan-Meier curves for all stroke (fatal or non-fatal).py, rather than control therapy, to prevent one stroke. Fatal
troke occurred in three patients in the candesartan group
nd seven in the control group (RR  0.44, p  0.20).
on-fatal stroke occurred in 17 candesartan patients and 28
ontrol patients (RR  0.61, p  0.109 unadjusted, p 
.110 adjusted). There was little difference between the
reatment groups in the occurrence of fatal or non-fatal
yocardial infarctions, CV deaths, or deaths from all causes
Table 3).
At baseline, in patients with ISH, the mean MMSE score
as 28.6 in both the candesartan and control groups. There
as no significant difference in change in MMSE score
etween the treatment groups during the study (candesartan
0.58, control 0.64, p  0.20). Dementia occurred in
.1% of the patients in the candesartan group and in 2.7%
f the patients in the control group (p  0.20). There was
trend toward fewer patients developing new diabetes in
he candesartan group than in the control group (3.4% vs.
.7%, p  0.20).
Treatment was generally well tolerated in both groups. A
imilar proportion of patients in the candesartan group and
he control group discontinued treatment because of adverse
vents (candesartan 17.3%, control 17.6%), whether consid-
red related to the study drug or not. The most common
dverse events reported were dizziness/vertigo, accident/
njury, back pain, and bronchitis, and they occurred in
imilar proportions of patients in both treatment groups.
ISCUSSION
he present study demonstrated a substantial, 42% RR
eduction in all stroke (fatal  non-fatal) in elderly patients
ith ISH treated with a candesartan-based regimen com-
ared with a comparator regimen, mostly diuretic-based.
his risk reduction achieved statistical significance after
djustment for the slightly higher CV risk at baseline in the
andesartan group, despite the overall small number of
vents. The favorable effect of candesartan-based therapy
as observed despite a very small blood pressure difference
Events/
1,000 Follow-Up Years
RR (95% CI)* p Value*ndesartan Control
27.3 30.8 0.890 (0.652–1.214) 0.461
16.8 16.9 1.00 (0.669–1.495) 1.00
8.3 8.9 0.932 (0.529–1.642) 0.807
7.2 12.5 0.577 (0.333–1.000) 0.050
2.1 2.5 0.871 (0.293–2.593) 0.804
6.5 7.1 0.911 (0.482–1.723) 0.775
1.1 2.5 0.443 (0.115–1.714) 0.238
6.1 10.0 0.611 (0.334–1.116) 0.109
29.3 31.7 0.928 (0.688–1.251) 0.623
ssion.
n; RR  relative risk.Ca
regreetween the candesartan and control groups. It may there-
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September 15, 2004:1175–80 Stroke Prevention in ISHore be suggested that at least part of the beneficial effect
bserved is due to specific vascular protective effects of
T1-receptor blockade.
No statistically significant differences between the treat-
ent groups were noted in any other individual health
utcome measure, although trends toward benefit with
andesartan-based treatment were noted for several end
oints, for example, major CV events, all myocardial infarc-
ion (fatal  non-fatal), all-cause death, and new-onset
iabetes mellitus. The observed risk reduction in stroke with
andesartan-based therapy is important not only because
troke is a disabling and much feared complication of
ypertension, it is also the predominant complication in
lderly patients with hypertension. As noted in recent trials
5) and also observed in the SCOPE, strokes have surpassed
oronary events in treated older patients with hypertension.
The estimated mean RR reduction in all stroke with
andesartan was greater in patients with ISH (42%) than in
he entire SCOPE population (24%), or in the non-ISH
opulation (16%). However, this does not preclude similar
enefit in ISH and non-ISH patients, because the 95% CI
ere wide (because of relatively few events) and overlapping,
nd the interaction test (treatment by ISH/non-ISH) was
on-significant (p  0.20).
There was no significant difference between the treat-
ent groups with respect to cognitive function as measured
y MMSE or dementia in patients with ISH. This was
imilar to the overall study results (8). There was a marked
eduction, 28%, in new-onset diabetes in the candesartan
roup compared with the control group in this subset of
atients, although not statistically significant. These obser-
ations are consistent with the results of the main analysis,
ncluding the entire SCOPE study population, and possible
xplanations have been discussed (8).
The stroke results in patients with ISH in the SCOPE
re in line with the results reported by the LIFE investiga-
ors in a similar analysis of patients with ISH (6). Patients
n LIFE with ISH, treated with losartan experienced 40%
ewer strokes, 46% lower CV mortality, and 38% lower
ew-onset diabetes as compared with those treated with
tenolol. Although the two studies have similarities, they
lso differ in several important aspects: Patients in the LIFE
rial were selected to be hypertensive with left ventricular
ypertrophy, whereas patients in the SCOPE were of high
ge, both known strong independent markers of increased
isk for CV events. However, the rate of stroke per 1,000
atient-years was 10.6 for losartan and 18.9 for atenolol in
he LIFE trial and 6.1 for candesartan and 10.0 for control
n the SCOPE. The comparator in the LIFE trial was a
eta-blocker, whereas in the SCOPE it was mostly a
iuretic.
There were fewer events in the SCOPE than originally
xpected, probably at least partly because of extensive
ntihypertensive treatment in the control group. This re-
uces the power of the statistical analyses and is a limitation
f the trial, especially when subgroups of patients are tonsidered. For example, there were only a total of 55
trokes in the ISH patients.
It is important to note that the SCOPE was conducted in
lderly patients, a population in which ISH is the dominant
ubtype of hypertension. The median age of the ISH
articipants in the SCOPE was 77.3 years, and nearly 30%
f the patients were 80 years old or above. In comparison,
he study populations in the SHEP and the Syst-Eur trials
ere younger (mean age, 70 to 72 years) (3,4).
Blood pressure reduction was slightly better (2.0/1.2 mm
g) with the candesartan-based regimen compared with the
ontrol regimen, but the difference was not statistically
ignificant. It is possible that these relatively small differ-
nces in blood pressure could account for part of the
bserved clinical benefit on stroke. In the Antihypertensive
nd Lipid-Lowering treatment to prevent Heart Attack
rial (ALLHAT), use of the diuretic chlorthalidone low-
red SBP by only 2 mm Hg more than the angiotensin-
onverting enzyme inhibitor lisinopril, yet resulted in a 15%
ower risk of stroke (p  0.02) (10). Other studies have
ikewise demonstrated the impact of incremental reductions
n blood pressure on stroke. Reducing DBP by 2 mm Hg in
reviously untreated hypertensive patients has been esti-
ated to prevent 15% of strokes (11), and similar results
ave been estimated for small reductions in SBP (12). A
ecent meta-analysis (13) of data from close to one million
dults from 61 prospective, observational studies showed the
mpact of small changes in SBP or DBP. The risk of stroke
as incremental and continuous from SBP of 115 mm Hg
nd above. These observations indicate that the small
ifference in blood pressure between the treatment groups in
he SCOPE could account for a difference in stroke of
pproximately 15%.
Thus, it is possible that the favorable effect on stroke in
he ARB-treated groups in both the SCOPE and LIFE
rials is related to AT1-receptor blockade (and/or AT2-
eceptor activation) and not just to blood pressure lowering.
he hypothesis of cerebroprotection by AT2-receptor acti-
ation has recently been emphasized (14). It is supported by
everal animal studies (15–21) that indicate neuroprotective
ffects of specific AT1-receptor blockade at concentrations
ot affecting blood pressure. Similarly, results from clinical
rials indicate that specific AT1-receptor blockade may have
alue in the secondary prevention of stroke, which cannot be
ully explained by blood pressure reduction (22).
ONCLUSIONS
n elderly patients with ISH, antihypertensive treatment
ased on the ARB candesartan resulted in a significant 42%
R reduction in stroke in comparison with other antihy-
ertensive treatment, despite little difference in blood pres-
ure reduction. This finding is particularly important given
he high stroke risk in this elderly hypertensive population.
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